TrademarkDir
EPISMART
LIVE

Serial Number

87113634

Owner

EPION THERAPEUTICS, INC.

Attorney

Susan Neuberger Weller

First Use Date

Dec 18, 2016

Filing Date

Jul 22, 2016

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

EPISMART Trademark

Serial Number: 87113634 • Registration: 6130549

EPISMART is a trademark filed by EPION THERAPEUTICS, INC. on July 22, 2016. The trademark is classified under Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

EPION THERAPEUTICS, INC. (7 trademarks)

1500 DISTRICT AVENUE
BURLINGTON, MA 01803

Entity Type: 03

CXL OPHTHALMICS, INC. (7 trademarks)

4354 MANCHESTER AVENUE
ENCINITAS, CA 92024

Entity Type: 03

CXL Ophthalmics, LLC (8 trademarks)

Encinitas, CA 92024

Entity Type: 16

Trademark Details

Filing Date

July 22, 2016

Registration Date

August 18, 2020

First Use Anywhere

December 18, 2016

First Use in Commerce

July 3, 2020

Published for Opposition

May 16, 2017

Goods & Services

Medical apparatus and instruments for use in connection with ophthalmic treatments and examination, namely, a corneal strengthening system comprising ophthalmic solutions, eye sponges, therapeutic light emission devices and structural parts therefor

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Aug 18, 2025 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 22, 2023 ASGN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 5, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 5, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 5, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 5, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 5, 2023 COAR
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 19, 2023 ASGN
REGISTERED-PRINCIPAL REGISTER
Aug 18, 2020 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jul 14, 2020 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jul 13, 2020 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jul 9, 2020 SUPC
USE AMENDMENT FILED
Jul 7, 2020 IUAF
TEAS STATEMENT OF USE RECEIVED
Jul 7, 2020 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 3, 2020 EXRA
SOU EXTENSION 5 GRANTED
Jan 2, 2020 EX5G
SOU EXTENSION 5 FILED
Dec 31, 2019 EXT5
SOU TEAS EXTENSION RECEIVED
Dec 31, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 6, 2019 EXRA
SOU EXTENSION 4 GRANTED
Jul 5, 2019 EX4G
SOU EXTENSION 4 FILED
Jul 3, 2019 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 3, 2019 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 17, 2019 TCCA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 15, 2019 EXRA
SOU EXTENSION 3 GRANTED
Jan 14, 2019 EX3G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 14, 2019 AITU
SOU EXTENSION 3 FILED
Jan 2, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 2, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 10, 2018 EXRA
SOU EXTENSION 2 GRANTED
Jul 6, 2018 EX2G
SOU EXTENSION 2 FILED
Jul 6, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 6, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 11, 2018 EXRA
SOU EXTENSION 1 GRANTED
Jan 9, 2018 EX1G
SOU EXTENSION 1 FILED
Jan 9, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 9, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 11, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 16, 2017 NPUB
PUBLISHED FOR OPPOSITION
May 16, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 26, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 6, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 16, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 15, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 9, 2016 GNRN
NON-FINAL ACTION E-MAILED
Nov 9, 2016 GNRT
NON-FINAL ACTION WRITTEN
Nov 9, 2016 CNRT
ASSIGNED TO EXAMINER
Nov 2, 2016 DOCK
NOTICE OF PSEUDO MARK E-MAILED
Jul 29, 2016 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 28, 2016 NWOS
NEW APPLICATION ENTERED
Jul 26, 2016 NWAP

Related Trademarks

More from this Owner

EPION

EPION

EPION

EPION

EPION THERAPEUTICS

EPION THERAPEUTICS

EPION THERAPEUTICS

EPION THERAPEUTICS

CXLO

CXLO

CXLO

CXLO